Photocure Reports Strong Q1 2026 Growth, Eyes FDA Reclassification for BLC Expansion
Event summary
- Photocure reported Q1 2026 revenues of NOK 139.0 million for Hexvix®/Cysview®, up from NOK 125.3 million in Q1 2025, with adjusted EBITDA of NOK 15.3 million.
- The company installed 11 new Saphira towers in the U.S., bringing the total active accounts to 413, a 21% increase year-over-year.
- Total revenues reached NOK 264.6 million, including NOK 125.6 million in milestone payments for Cevira approvals in China and Europe.
- FDA clarified the reclassification pathway for BLC equipment, potentially unlocking a larger commercial opportunity for Photocure.
- Photocure made a $3.0 million investment in Vesica Health to advance precision diagnostics for bladder cancer.
The big picture
Photocure's Q1 2026 results highlight its strong commercial execution and strategic investments in expanding its blue-light cystoscopy (BLC) technology. The FDA's clarification on BLC equipment reclassification could significantly broaden Photocure's market opportunity, while its investments in precision diagnostics align with the industry's shift toward personalized and data-driven care pathways. The company's ability to navigate regulatory dynamics and sustain growth will be critical in maintaining its momentum.
What we're watching
- Regulatory Headwinds
- The pace at which FDA reclassification of BLC equipment progresses will determine the scale of Photocure's commercial expansion in the U.S.
- Commercial Execution
- Whether Photocure can sustain its 7-11% product revenue growth amid increasing competition and regulatory shifts.
- Strategic Investments
- How Photocure's investments in precision diagnostics and AI-enabled software will impact its long-term diagnostic platform strategy.
Related topics